What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2018-06-19 compared with 2017-12-15 · 16 added, 26 removed, 95 unchanged (31% of the section changed)

Other Information

Exhibit Number

Articles of Incorporation and Bylaws

48 unchanged sentences

Plan of Merger and Acquisition Agreement between our company and IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated by reference to our Current Report on Form 8-K filed on November 23, 2015 and our Current Report on Form 8-K/A filed on February 3, 2016)

Plan of Merger and Acquisition Agreement between our company and IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated by reference to our Current Report on Form 8‑K filed on November 23, 2015 and our Current Report on Form 8‑K/A filed on February 3, 2016)

Employment Agreement dated November 20, 2015 with Dr.

Pravin Chaturvedi (incorporated by reference to our Quarterly Report on Form 10-Q filed on December 15, 2015)

Employment Agreement dated November 20, 2015 with Dr.

Pravin Chaturvedi (incorporated by reference to our Quarterly Report on Form 10‑Q filed on December 15, 2015)

Employment Agreement dated February 1, 2016 with Dr.

Ahmad Doroudian (filed on April 29, 2016 with our Annual Report on Form 10-K)

Employment Agreement dated February 1, 2016 with Dr.

Ahmad Doroudian (filed on April 29, 2016 with our Annual Report on Form 10-K)

Employment Agreement dated February 1, 2016 with Moira Ong (filed on April 29, 2016 with our Annual Report on Form 10-K)

Consulting Services Agreement dated February 1, 2016 with Soho Capital Inc.

(filed on April 29, 2016 with our Annual Report on Form 10-K)

Consulting Services Agreement dated February 1, 2016 with Soho Capital Inc.

(filed on April 29, 2016 with our Annual Report on Form 10-K)

Convertible debenture agreement dated September 29, 2016 with Avro Capital Partners Inc.

Exchange Agreement between our company, IndUS Pharmaceuticals, Inc.

and Pravin Chaturvedi, dated September 11, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)

(incorporated by reference to our Quarterly Report on Form 10-Q filed on September 14, 2017)

Exchange Agreement between our company, IndUS Pharmaceuticals, Inc.

2 unchanged sentences

dated September 12, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)

Licensing Agreement between our company and Altum Pharmaceuticals Inc.

dated September 12, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)

Debt Forgiveness Agreement dated July 31, 2017 between our company and Dr.

Ahmad Doroudian (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)

Debt Forgiveness Agreement dated July 31, 2017 between our company and Dr.

Ahmad Doroudian (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)

Debt Forgiveness Agreement dated July 31, 2017 between our company and Moira Ong (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)

Debt Forgiveness Agreement dated July 31, 2017 between our company and Soho Capital Inc.

(filed on September 15, 2017 with our Quarterly Report on Form 10-Q)

Debt Forgiveness Agreement dated July 31, 2017 between our company and Soho Capital Inc.

(filed on September 15, 2017 with our Quarterly Report on Form 10-Q)

Debt Settlement Agreement dated September 18, 2017 between our company and Avro Capital Partners, Inc.

Collaboration and License Agreement dated September 23, 2017 between our company and SolMic GmbH

Letter of Intent dated November 7, 2017 between our company and Thrudermic LLC

(filed on December 15, 2017 with our Quarterly Report on Form 10-Q)

Collaboration and License Agreement dated September 23, 2017 between our company and SolMic GmbH (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)

Letter of Intent dated November 7, 2017 between our company and Thrudermic LLC (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)

Share Exchange Agreement between our company, ERS Holdings, LLC and the members of ERS Holdings, LLC dated February 10, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

Royalty Agreement between our company and AquaBrew Inc.

dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

Employment Agreement between our company and Patrick Rolfes dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

Share Exchange Agreement between our company, Thrudermic, LLC, Dr.

Joseph Borovsky and Dr.

Leonid Lurya dated March 2, 3018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

Employment Agreement between our company and Joseph Borovsky dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

10% Senior Secured Convertible Debenture (CDN$2,500,000) due March 2, 2019 (CD-1) (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

10% Senior Secured Convertible Debenture (CDN$2,500,000) due March 2, 2019 (CD-2) (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)

Rule 13a-14(d)/15d-14(d) Certifications

17 unchanged sentences

PIVOT PHARMACEUTICALS INC.

December 15, 2017

June 19, 2018

/s/ Patrick Frankham

2 unchanged sentences

(Principal Executive Officer)

December 15, 2017

June 19, 2018

/s/ Moira Ong

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information